Firsekibart Shown Safe in Phase 1 Study
In a groundbreaking Phase 1 clinical trial conducted in China, researchers have investigated Firsekibart, a novel anti-interleukin-1β monoclonal antibody, through ...
In a groundbreaking Phase 1 clinical trial conducted in China, researchers have investigated Firsekibart, a novel anti-interleukin-1β monoclonal antibody, through ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine